Ginkgo Bioworks Holdings, Inc. (DNA): Cash & Equivalents
$167.20M
As of 2025-12-31
$84.53M
As of 2026-06-30
-49.7%
3-year compound annual growth
-15.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $167.20M | -70.2% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $561.57M | -40.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $944.07M | -28.3% | 2026-02-26, Balance as of period end |
| 2022-12-31 | $1.32B | -15.1% | 2025-02-25, Balance as of period end |
| 2021-12-31 | $1.55B | +307.0% | 2024-02-29, Balance as of period end |
| 2020-12-31 | $380.80M | -23.1% | 2023-03-13, Balance as of period end |
| 2019-12-31 | $495.29M | n/a | 2022-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $167.20M | -70.2% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $91.14M | -36.7% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $294.94M | +4.6% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $8.48M | -66.1% |
| Agenus Inc (AGEN) | 2025-12-31 | $3.00M | -92.6% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $163.08M | +41.0% |
Compare DNA, RGNX, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗